Open AccessGlycemic control after initiating direct-acting antiviral agents in patients with hepatitis C virus and type 2 diabetes mellitus using the united states integrated healthcare system
Author(s) -
Angela Wong,
John L. Sie,
Angela Chen,
Basuki Gunawan,
Joanie Chung,
Nazia Rashid
Publication year - 2020
Publication title -
journal of research in pharmacy practice
Language(s) - English
Resource type - Journals
eISSN - 2319-9644
pISSN - 2279-042X
DOI - 10.4103/jrpp.jrpp_19_110
Subject(s) - medicine , sofosbuvir , glycemic , hepatitis c virus , type 2 diabetes mellitus , diabetes mellitus , population , hepatitis c , type 2 diabetes , gastroenterology , virus , immunology , ribavirin , insulin , endocrinology , environmental health
Hepatitis C virus (HCV) has an increased risk of Type 2 diabetes mellitus (T2DM). Prior studies found that the eradication of HCV with direct-acting antiviral (DAA) agents led to improved glycemic control in patients with T2DM. We aimed to identify the association between HCV eradication and glycemic control in patients diagnosed with HCV and T2DM.